http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 08:01:36 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Voyager+gets+FDA+clearance+for+first+tau+gene+therapy+for+Alzheimer%27s/26579588.html <p>Voyager Therapeutics Inc. (NASDAQ: VYGR) received U.S. Food and Drug Administration clearance for its Investigational New Drug application for VY1706, a gene therapy targeting tau protein in Alzheimer's disease patients. The company plans to begin dosing adults with early Alzheimer's disease in the second half of 2026.</p><p>VY1706 uses a vectorized siRNA that targets MAPT mRNA to reduce both intracellular and extracellular tau levels in the brain. The therapy is delivered through a single intravenous dose using Voyager's TRACER AAV capsid technology, which targets a receptor called ALPL to transport the treatment across the blood-brain barrier.</p><p>The upcoming clinical trial will be http://www.streetinsider.com/Corporate+News/Voyager+gets+FDA+clearance+for+first+tau+gene+therapy+for+Alzheimer%27s/26579588.html Mon, 01 Jun 2026 08:01:36 -0400 VYGR http://www.streetinsider.com/FDA/Voyager+gets+FDA+clearance+for+first+tau+gene+therapy+for+Alzheimer%27s/26579588.html <p>Voyager Therapeutics Inc. (NASDAQ: VYGR) received U.S. Food and Drug Administration clearance for its Investigational New Drug application for VY1706, a gene therapy targeting tau protein in Alzheimer's disease patients. The company plans to begin dosing adults with early Alzheimer's disease in the second half of 2026.</p><p>VY1706 uses a vectorized siRNA that targets MAPT mRNA to reduce both intracellular and extracellular tau levels in the brain. The therapy is delivered through a single intravenous dose using Voyager's TRACER AAV capsid technology, which targets a receptor called ALPL to transport the treatment across the blood-brain barrier.</p><p>The upcoming clinical trial will be http://www.streetinsider.com/FDA/Voyager+gets+FDA+clearance+for+first+tau+gene+therapy+for+Alzheimer%27s/26579588.html Mon, 01 Jun 2026 08:01:36 -0400 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Press+Releases/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html <p align="center"><em>- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 -</em></p> <p align="center"><em>- Comprehensive preclinical program showed compelling pharmacology and safety profile for VY1706 -</em></p> <p align="center"><em>- VY1706 uses an IV-delivered, brain-targeted capsid to reduce intracellular and extracellular tau -</em></p> <p>LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for VY1706, the Company’s investigational gene therapy targeting http://www.streetinsider.com/Globe+Newswire/Voyager+Receives+FDA+IND+Clearance+for+VY1706%2C+First+Gene+Therapy+Approach+to+Reducing+Tau+Production+in+the+Brain+for+Alzheimer%E2%80%99s+Disease/26579487.html Mon, 01 Jun 2026 08:00:00 -0400 A.06822034 O.17919569 O.20026344 VYGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+01/26579550.html si-local-file:///var/storage/secattach/20260601/26579550.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+01/26579550.html Mon, 01 Jun 2026 08:00:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+01/26579550.html si-local-file:///var/storage/secattach/20260601/26579550.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Voyager+Therapeutics%2C+++++For%3A+Jun+01/26579550.html Mon, 01 Jun 2026 08:00:00 -0400 O.17919569 VYGR http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Voyager+Therapeutics+%28VYGR%29/26545588.html <p>H.C. Wainwright analyst Patrick R. Trucchio reiterated a Buy rating and $25.00 price target on Voyager Therapeutics (NASDAQ: VYGR).</p><p>The analyst commented: "Voyager started 2026 with clear pipeline momentum including the completion of a key investigational new drug (IND)-enabling good laboratory practice (GLP) toxicology study for its wholly-owned VY1706 program—a one-time intravenously (IV) administered tau-silencing gene therapy in Alzheimer’s disease — positioning an IND filing on-track for 2Q26, with a potential first-in-human study start in 2H26. The data from the VY1706 GLP tox study were presented by Chief Scientific Officer Todd Carter, Ph.D., in a late-breaking oral presentation at the American http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Voyager+Therapeutics+%28VYGR%29/26545588.html Tue, 26 May 2026 06:58:34 -0400 VYGR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Voyager+Therapeutics%2C+++++For%3A+May+08++Filed+by%3A+Quinlan+Amy/26513549.html si-local-file:///var/storage/secattach/20260518/26513549.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Voyager+Therapeutics%2C+++++For%3A+May+08++Filed+by%3A+Quinlan+Amy/26513549.html Mon, 18 May 2026 16:01:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Voyager+Therapeutics%2C+++++For%3A+May+08++Filed+by%3A+Quinlan+Amy/26513549.html si-local-file:///var/storage/secattach/20260518/26513549.html http://www.streetinsider.com/SEC+Filings/Form++3++++++++++Voyager+Therapeutics%2C+++++For%3A+May+08++Filed+by%3A+Quinlan+Amy/26513549.html Mon, 18 May 2026 16:01:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26505337.html si-local-file:///var/storage/secattach/20260515/26505337.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26505337.html Fri, 15 May 2026 16:13:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26505337.html si-local-file:///var/storage/secattach/20260515/26505337.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26505337.html Fri, 15 May 2026 16:13:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26503753.html si-local-file:///var/storage/secattach/20260515/26503753.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26503753.html Fri, 15 May 2026 14:17:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26503753.html si-local-file:///var/storage/secattach/20260515/26503753.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+EcoR1+Capital%2C+LLC/26503753.html Fri, 15 May 2026 14:17:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26501915.html si-local-file:///var/storage/secattach/20260515/26501915.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26501915.html Fri, 15 May 2026 11:04:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26501915.html si-local-file:///var/storage/secattach/20260515/26501915.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+ARMISTICE+CAPITAL%2C+LLC/26501915.html Fri, 15 May 2026 11:04:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26501642.html si-local-file:///var/storage/secattach/20260515/26501642.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26501642.html Fri, 15 May 2026 10:35:00 -0400 O.17919569 VYGR http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26501642.html si-local-file:///var/storage/secattach/20260515/26501642.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++Voyager+Therapeutics%2C++++++++++++++++++Filed+by%3A+Jorgensen+Nathan+D./26501642.html Fri, 15 May 2026 10:35:00 -0400 O.17919569 VYGR http://www.streetinsider.com/Corporate+News/Voyager+presents+positive+safety+data+for+Alzheimer%27s+gene+therapy+VY1706/26480845.html <p>Voyager Therapeutics Inc. (NASDAQ: VYGR) reported positive three-month toxicology data for VY1706, its investigational tau silencing gene therapy for Alzheimer's disease, at the American Society of Gene & Cell Therapy's 2026 Annual Meeting in Boston.</p><p>The study showed VY1706 was well tolerated with no adverse clinical pathology or histopathological findings up to the highest dose tested of 5E13 vg/kg in non-human primates. The single intravenous dose reduced tau protein by up to 64% in key brain regions at 13 weeks following treatment.</p><p>The company's FDA investigational new drug application process for VY1706 remains on track for the second quarter of 2026, with http://www.streetinsider.com/Corporate+News/Voyager+presents+positive+safety+data+for+Alzheimer%27s+gene+therapy+VY1706/26480845.html Wed, 13 May 2026 06:02:27 -0400 VYGR http://www.streetinsider.com/FDA/Voyager+presents+positive+safety+data+for+Alzheimer%27s+gene+therapy+VY1706/26480845.html <p>Voyager Therapeutics Inc. (NASDAQ: VYGR) reported positive three-month toxicology data for VY1706, its investigational tau silencing gene therapy for Alzheimer's disease, at the American Society of Gene & Cell Therapy's 2026 Annual Meeting in Boston.</p><p>The study showed VY1706 was well tolerated with no adverse clinical pathology or histopathological findings up to the highest dose tested of 5E13 vg/kg in non-human primates. The single intravenous dose reduced tau protein by up to 64% in key brain regions at 13 weeks following treatment.</p><p>The company's FDA investigational new drug application process for VY1706 remains on track for the second quarter of 2026, with http://www.streetinsider.com/FDA/Voyager+presents+positive+safety+data+for+Alzheimer%27s+gene+therapy+VY1706/26480845.html Wed, 13 May 2026 06:02:27 -0400 VYGR